Tubular carcinoma of the breast

Prognosis and response to adjuvant systemic therapy

P. R B Kitchen, H. J. Smith, M. A. Henderson, A. Goldhirsch, M. Castiglione-Gertsch, A. S. Coates, B. Gusterson, R. W. Brown, R. D. Gelber, J. P. Collins

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Tubular carcinoma of the breast is an uncommon and usually small tumour, and is thought to have a favourable prognosis. The present study examined the long-term prognosis of patients with tubular breast carcinoma and the roles of axillary dissection and adjuvant therapy. Methods: Eighty-six tubular cases were identified from a large worldwide database of 9520 breast carcinoma patients entered into randomized adjuvant therapy trials run by the International Breast Cancer Study Group from 1978 to 1999. These patients were followed for a median of 12 years. Results: Forty-two (49%) cases were node-positive, of which 33 (79%) had 1-3 nodes involved. Ten (32%) of the 31 smaller tumours (≤1 cm in size) were node-positive. Patients with node-positive tubular carcinoma had a significantly better 10-year relapse-free survival (P = 0.006) and survival (P <0.0001) compared with non-tubular node-positive cases. Overall survival was similar for nodepositive and node-negative tubular carcinoma. Overall, 71 patients (83%) received some form of adjuvant systemic therapy. Of the 86 cases, 43 (50%) received more than one course of chemotherapy. There was an 85% decrease in the risk of death for patients who received more than one course of chemotherapy compared to those who did not (hazard ratio 0.15, 95% confidence interval (CI): 0.03-0.82; P = 0.03). Conclusions: Compared to other histological types of breast cancer, tubular carcinoma has a better long-term prognosis. Adjuvant chemotherapy may further improve prognosis and involvement of axillary nodes may not be an indicator for early death due to breast carcinoma.

Original languageEnglish
Pages (from-to)27-31
Number of pages5
JournalAustralian and New Zealand Journal of Surgery
Volume71
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Adenocarcinoma
Breast
Breast Neoplasms
Survival
Therapeutics
Drug Therapy
Adjuvant Chemotherapy
Dissection
Neoplasms
Databases
Confidence Intervals
Recurrence

Keywords

  • Adjuvant chemotherapy
  • Breast neoplasms
  • Tubular breast carcinoma

ASJC Scopus subject areas

  • Surgery

Cite this

Kitchen, P. R. B., Smith, H. J., Henderson, M. A., Goldhirsch, A., Castiglione-Gertsch, M., Coates, A. S., ... Collins, J. P. (2001). Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. Australian and New Zealand Journal of Surgery, 71(1), 27-31. https://doi.org/10.1046/j.1440-1622.2001.02022.x

Tubular carcinoma of the breast : Prognosis and response to adjuvant systemic therapy. / Kitchen, P. R B; Smith, H. J.; Henderson, M. A.; Goldhirsch, A.; Castiglione-Gertsch, M.; Coates, A. S.; Gusterson, B.; Brown, R. W.; Gelber, R. D.; Collins, J. P.

In: Australian and New Zealand Journal of Surgery, Vol. 71, No. 1, 2001, p. 27-31.

Research output: Contribution to journalArticle

Kitchen, PRB, Smith, HJ, Henderson, MA, Goldhirsch, A, Castiglione-Gertsch, M, Coates, AS, Gusterson, B, Brown, RW, Gelber, RD & Collins, JP 2001, 'Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy', Australian and New Zealand Journal of Surgery, vol. 71, no. 1, pp. 27-31. https://doi.org/10.1046/j.1440-1622.2001.02022.x
Kitchen, P. R B ; Smith, H. J. ; Henderson, M. A. ; Goldhirsch, A. ; Castiglione-Gertsch, M. ; Coates, A. S. ; Gusterson, B. ; Brown, R. W. ; Gelber, R. D. ; Collins, J. P. / Tubular carcinoma of the breast : Prognosis and response to adjuvant systemic therapy. In: Australian and New Zealand Journal of Surgery. 2001 ; Vol. 71, No. 1. pp. 27-31.
@article{2dfe14932d83434690944d12364b41e0,
title = "Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy",
abstract = "Background: Tubular carcinoma of the breast is an uncommon and usually small tumour, and is thought to have a favourable prognosis. The present study examined the long-term prognosis of patients with tubular breast carcinoma and the roles of axillary dissection and adjuvant therapy. Methods: Eighty-six tubular cases were identified from a large worldwide database of 9520 breast carcinoma patients entered into randomized adjuvant therapy trials run by the International Breast Cancer Study Group from 1978 to 1999. These patients were followed for a median of 12 years. Results: Forty-two (49{\%}) cases were node-positive, of which 33 (79{\%}) had 1-3 nodes involved. Ten (32{\%}) of the 31 smaller tumours (≤1 cm in size) were node-positive. Patients with node-positive tubular carcinoma had a significantly better 10-year relapse-free survival (P = 0.006) and survival (P <0.0001) compared with non-tubular node-positive cases. Overall survival was similar for nodepositive and node-negative tubular carcinoma. Overall, 71 patients (83{\%}) received some form of adjuvant systemic therapy. Of the 86 cases, 43 (50{\%}) received more than one course of chemotherapy. There was an 85{\%} decrease in the risk of death for patients who received more than one course of chemotherapy compared to those who did not (hazard ratio 0.15, 95{\%} confidence interval (CI): 0.03-0.82; P = 0.03). Conclusions: Compared to other histological types of breast cancer, tubular carcinoma has a better long-term prognosis. Adjuvant chemotherapy may further improve prognosis and involvement of axillary nodes may not be an indicator for early death due to breast carcinoma.",
keywords = "Adjuvant chemotherapy, Breast neoplasms, Tubular breast carcinoma",
author = "Kitchen, {P. R B} and Smith, {H. J.} and Henderson, {M. A.} and A. Goldhirsch and M. Castiglione-Gertsch and Coates, {A. S.} and B. Gusterson and Brown, {R. W.} and Gelber, {R. D.} and Collins, {J. P.}",
year = "2001",
doi = "10.1046/j.1440-1622.2001.02022.x",
language = "English",
volume = "71",
pages = "27--31",
journal = "Australian and New Zealand Journal of Surgery",
issn = "0004-8682",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Tubular carcinoma of the breast

T2 - Prognosis and response to adjuvant systemic therapy

AU - Kitchen, P. R B

AU - Smith, H. J.

AU - Henderson, M. A.

AU - Goldhirsch, A.

AU - Castiglione-Gertsch, M.

AU - Coates, A. S.

AU - Gusterson, B.

AU - Brown, R. W.

AU - Gelber, R. D.

AU - Collins, J. P.

PY - 2001

Y1 - 2001

N2 - Background: Tubular carcinoma of the breast is an uncommon and usually small tumour, and is thought to have a favourable prognosis. The present study examined the long-term prognosis of patients with tubular breast carcinoma and the roles of axillary dissection and adjuvant therapy. Methods: Eighty-six tubular cases were identified from a large worldwide database of 9520 breast carcinoma patients entered into randomized adjuvant therapy trials run by the International Breast Cancer Study Group from 1978 to 1999. These patients were followed for a median of 12 years. Results: Forty-two (49%) cases were node-positive, of which 33 (79%) had 1-3 nodes involved. Ten (32%) of the 31 smaller tumours (≤1 cm in size) were node-positive. Patients with node-positive tubular carcinoma had a significantly better 10-year relapse-free survival (P = 0.006) and survival (P <0.0001) compared with non-tubular node-positive cases. Overall survival was similar for nodepositive and node-negative tubular carcinoma. Overall, 71 patients (83%) received some form of adjuvant systemic therapy. Of the 86 cases, 43 (50%) received more than one course of chemotherapy. There was an 85% decrease in the risk of death for patients who received more than one course of chemotherapy compared to those who did not (hazard ratio 0.15, 95% confidence interval (CI): 0.03-0.82; P = 0.03). Conclusions: Compared to other histological types of breast cancer, tubular carcinoma has a better long-term prognosis. Adjuvant chemotherapy may further improve prognosis and involvement of axillary nodes may not be an indicator for early death due to breast carcinoma.

AB - Background: Tubular carcinoma of the breast is an uncommon and usually small tumour, and is thought to have a favourable prognosis. The present study examined the long-term prognosis of patients with tubular breast carcinoma and the roles of axillary dissection and adjuvant therapy. Methods: Eighty-six tubular cases were identified from a large worldwide database of 9520 breast carcinoma patients entered into randomized adjuvant therapy trials run by the International Breast Cancer Study Group from 1978 to 1999. These patients were followed for a median of 12 years. Results: Forty-two (49%) cases were node-positive, of which 33 (79%) had 1-3 nodes involved. Ten (32%) of the 31 smaller tumours (≤1 cm in size) were node-positive. Patients with node-positive tubular carcinoma had a significantly better 10-year relapse-free survival (P = 0.006) and survival (P <0.0001) compared with non-tubular node-positive cases. Overall survival was similar for nodepositive and node-negative tubular carcinoma. Overall, 71 patients (83%) received some form of adjuvant systemic therapy. Of the 86 cases, 43 (50%) received more than one course of chemotherapy. There was an 85% decrease in the risk of death for patients who received more than one course of chemotherapy compared to those who did not (hazard ratio 0.15, 95% confidence interval (CI): 0.03-0.82; P = 0.03). Conclusions: Compared to other histological types of breast cancer, tubular carcinoma has a better long-term prognosis. Adjuvant chemotherapy may further improve prognosis and involvement of axillary nodes may not be an indicator for early death due to breast carcinoma.

KW - Adjuvant chemotherapy

KW - Breast neoplasms

KW - Tubular breast carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0035174140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035174140&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1622.2001.02022.x

DO - 10.1046/j.1440-1622.2001.02022.x

M3 - Article

VL - 71

SP - 27

EP - 31

JO - Australian and New Zealand Journal of Surgery

JF - Australian and New Zealand Journal of Surgery

SN - 0004-8682

IS - 1

ER -